stockrow
Friday 6 November 2026
Export SGHT’s income statement to Excel — free account
Sight Sciences, Inc.
SGHT Healthcare Medical Devices
Sight Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $77.4 million, down 3.13% from fiscal 2024.
- Revenue
- +25.2%
- EPS
- +25.0%
- Free cash flow
- +72.2%
- Total debt
- +2.40%
Quarter to September 2026, against a year earlier
10.04
0.28
+2.87%
Follow SGHT
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 5 | 4 | 5 |
+8 more TTM periods Free account |
| (50.07%) | (48.42%) | (56.64%) | (50.74%) | ||
| (25.68%) | (26.24%) | (31.12%) | (29.77%) | ||
ROIC |
(127.79%) | (125.18%) | (235.20%) | (188.86%) | |
Return on Tangible Assets |
(34.20%) | (36.02%) | (41.41%) | (37.19%) | |
Average Days of Receivables |
55.25 | 49.84 | 48.61 | 45.98 | |
Free Cash Flow per Share |
(0.31) | (0.43) | (0.47) | (0.58) | |
Free Cash Flow |
(16.91) | (23.33) | (25.40) | (30.05) | |
Capital Expenditures |
0.01 | (0.09) | (0.28) | (0.36) | |
| Other line items | |||||
Cash ROIC |
(10.09%) | (13.45%) | (14.16%) | (15.32%) | |
Accounts Receivable Turnover |
7.65 | 7.94 | 7.95 | 7.54 | |
Accounts Payable Turnover |
4.79 | 5.05 | 5.18 | 7.05 | |
Inventory Turnover |
1.50 | 1.69 | 1.72 | 1.52 | |
Average Days of Payables |
93.73 | 69.00 | 49.29 | 45.83 | |
Days of Inventory on Hand |
219.05 | 207.04 | 232.44 | 265.02 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
11.54% | 13.01% | 15.99% | 18.88% | |
Selling, General and Administrative Expense of Revenue |
105.73% | 108.38% | 114.99% | 115.25% | |
Share Based Compensation of Revenue |
12.78% | 12.94% | 14.66% | 16.87% | |
Interest Coverage |
(5.06) | (5.41) | (6.93) | (7.21) | |
Operating CF/Net income |
0.60 | 0.78 | 0.67 | 0.77 | |
Depreciation/Fixed assets |
0.80 | 0.82 | 0.86 | 0.89 | |
Capex/Depreciation |
0.01 | (0.07) | (0.20) | (0.25) | |
Revenue per Share |
1.60 | 1.53 | 1.47 | 1.48 | |
Operating CF per Share |
(0.31) | (0.43) | (0.47) | (0.57) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 4 Nov 2026